2

| INFORMATION DISCLOSURE CITATION<br><br>*(Use several sheets if necessary)* | ATTY. DOCKET NO. PC10228B | SERIAL NO. Express Mail No. EL446402284US |
|---|---|---|
| | APPLICANT Farzan Rastinejad et al. | 09/863,976 |
| | FILING DATE May 23, 2001 | GROUP 1624 (anticipated) |

## U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

09/863976 U.S. PTO
05/23/01

## FOREIGN PATENT DOCUMENTS

| DOCUMENT NUMBER | | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | YES | NO |
| WO | 94/ | 1 | 2 | 2 | 0 | 2 | | 6/9/94 | PCT/GB | | | | |
| WO | 97/ | 3 | 7 | 6 | 4 | 5 | | 10/16/97 | PCT/US | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

## OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

| | | | |
|---|---|---|---|
| | | | Pierre Hainaut et al.; "Redox Modulation of p53 Conformation and Sequence-specific DNA Binding in vitro"; *Cancer Research* vol. 35, No. 18, pp. 4469-4473, (1993) |
| | | | James J. Ryan et al., "Alteration of p53 Conformation and Induction of Adoptosis in a Murine Erythroleukemia Cell Line By Dimethylsulfoxide"; *Leukemia Research*, vol. 18, No. 8, pp. 612-621; (1994) |
| | | | C. Randell Brown, et al., "Correcting Temperature-sensitive Protein Folding Defects"; *J.Clin. Investigations;* Vol. 99 No. 6, pp 1432-1444, (1997) |
| | | | P.V.M. Shekhar, et al., "Altered P53 conformation: A novel mechanism of wild-type p53 functional inactivation in a model for early human breast cancer"; *International Journal of Oncology,* vol. 11, No. 5, pp. 1087-1094, *(1997)* |
| | | | Pierre Hainut, et al., "A Structural Role for Metal Ions in the "Wild-type" Conformatin of the Tumor Suppressor Protein p53"; *Cancer Research*, vol. 53, no. 8 pp. 1739-1742, (1993) |
| | | | Blagoskonny, et al., "Geldanamycin selectivity destabilizes mutant p53" *Proc. Annu. Meet. Am. Assoc. Cancer Res.*, vol. 36, page 429, 1995, Abstract 2558 |
| | | | Hiroshi Sakagami et al., "Induction of DNA Fragmentation in Human Myelogenous Leukaemic Cell Lines by Phenothiazine-Related Compounds"; *Anticancer Research* 15 pp.2533-40 (1995) |
| | | | Mark A. Wuonola, et al., "The Primary in Vitro Antitumor Screening of "Half-Mustard Type" Phenothiazines"; *Anticancer Research*, 17 pp. 3409-3423, (1997) |
| | | | Sylvia Nagy, et al., "Antitumor Activity of Phenothiazine-Related Compounds" *Anticancer Research* 16, pp. 1915-1918, (1996) |
| | | | Noboru Motohashi, et al., "Synthesis and Antitumor Activity of 1-[2-(Chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-1-Ureas as Potent Anticancer Agents"; *Anticancer Research*, vol. 16, pp. 2525-2532 (1996) |
| | | | Marek Gniazdowsky, et al., "Thiol-Dependent Inhibition of RNA Synthesis in vitro By Acridines, Structure-Inhibition Relationships, *Cancer Letters*, 15, pp. 73-79 (1982) |

| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | ATTY. DOCKET NO. PC10228B | SERIAL NO. 09/863,976 |
|---|---|---|
| | APPLICANT Farzan Rastinejad et al. | |
| | FILING DATE May 23 2001 | GROUP 1614 |

MAY 1 5 2002

## U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |

## FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES | TRANSLATION NO |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | |
| | WO | 02/24692 | 3/28/02 | PCT | | | | |

## OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

| | | | |
|---|---|---|---|
| | | | M. Hollstein et al., "*Database of p53 gene somatic mutations in human tumors and cell lines*", Nucleic Acids Research, vol. 22, p. 3551-3555, (1994) |
| | | | P.M. O'Connor et al., "*Characterization of the p53 Tumor Suppressor Pathway in Cell Lines of the National Cancer Institute Anticancer Drug Screen and Correlations with the Growth Inhibitory Potency of 123 Anticancer Agents*", Cancer Research, vol. 57, p. 4285-4300 (1997) |
| | | | A. N. Bullock et al., "*Rescuing The Function of Mutant p53*", Nature Reviews, vol. 1, pp. 68-76, (2001) |
| | | | Martin L. Smith et al., "*Chemotherapeutic Targeting of p53*", Cancer Biology & Therapy, Internet pre-published on Sept. 5, 2001 as Manuscript MS # 08-30-02 |
| | | | Jackson B. Gibbs, "*Mechanism-Based Target Identification and Drug Discovery in Cancer Research*", Science Magazine, vol. 287, pp-1969-1973 (2000) |
| | | | Elizabeth Pennisi, "*Bracing p53 for the War on Cancer*", Science Magazine, vol. 286, p. 2431 (1999) |
| | | | Rishu Takimoto et al., "*The Mutant p53 Conformation Modifying Drug, CP-31398, Can Induce Apoptosis of Human Cancer Cells and can Stabilize Wild-Type p53 Protein*", Cancer Biology & Therapy, Internet pre-published on September 4, 2001 as Manuscript MS# 08-08-01 |
| | | | Barbara A. Foster et al., Science Magazine, "*Pharmacological Rescue of Mutant p53 Conformation and Function*", vol. 286, pp.2507-2510 (1999) |
| | | | Craig Caldwell et al., "*The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth*", Gene, vol. 277 pp. 15-30 (2001) |
| | | | The Journal of Antibiotics, *Lucilactaene, a New Cell Cycle Inhibitor in p53-Transfected Cancer Cells*", vol. 54, pp. 850-854 (2001) |
| | | | Jun-Li Luo, et al "*UV-induced DNA Damage and Mutations in Hupki (Human p53 Knock-in) Mice Recapitulate p53 Hotspot Alterations in Sun-exposed Human Skin*", Cancer Research, vol. 61, pp. 8158-8163 (2001) |
| | | | Foster et al. Science (1999), 286 (5449), 2507-2510 Abstract Only |

EXAMINER [signature] DATE CONSIDERED 9/17/02

COPY OF PAPERS ORIGINALLY FILED

RECEIVED
MAY 2 0 2002
TECH CENTER 1600/2900